Dawnrays Pharmaceutical (Holdings) (HKSE:02348) Buildings And Improvements : HK$854 Mil (As of Dec. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Dawnrays Pharmaceutical (Holdings) Buildings And Improvements?

Dawnrays Pharmaceutical (Holdings)'s quarterly buildings and improvements declined from Dec. 2023 (HK$647 Mil) to Jun. 2024 (HK$0 Mil) but then increased from Jun. 2024 (HK$0 Mil) to Dec. 2024 (HK$854 Mil).

Dawnrays Pharmaceutical (Holdings)'s annual buildings and improvements increased from Dec. 2022 (HK$602 Mil) to Dec. 2023 (HK$647 Mil) and increased from Dec. 2023 (HK$647 Mil) to Dec. 2024 (HK$854 Mil).

Dawnrays Pharmaceutical (Holdings) Buildings And Improvements Historical Data

The historical data trend for Dawnrays Pharmaceutical (Holdings)'s Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dawnrays Pharmaceutical (Holdings) Buildings And Improvements Chart

Dawnrays Pharmaceutical (Holdings) Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buildings And Improvements

Get a 7-Day Free Trial

376.13

306.12

601.95

647.37

854.23

Dawnrays Pharmaceutical (Holdings) Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Buildings And Improvements	Get a 7-Day Free Trial															601.95	-	647.37	-	854.23

Dawnrays Pharmaceutical (Holdings) Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Dawnrays Pharmaceutical (Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dawnrays Pharmaceutical (Holdings) Ltd (HKSE:02348) » Definitions » Buildings And Improvements

Traded in Other Exchanges

N/A

Address

338 Hennessy Road, Units 3001-02, 30th Floor, CNT Tower, Wanchai, North Sea Centre, Hong Kong, HKG

Website

https://www.dawnrays.com

Dawnrays Pharmaceutical (Holdings) Ltd is a drug manufacturing company. The company operates two segments, including Intermediates and Bulk Medicines, and Finished Drugs. The revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth plan.

Executives

Li Kei Ling
Hung Yung Lai
Fortune United Group Limited	2101 Beneficial owner
Hunwick International Limited	2201 Interest of corporation controlled by you
Keysmart Enterprises Limited	2201 Interest of corporation controlled by you
Iu Pun	2202 Interest of your spouse
Li Tung Ming
Fmr Llc	2201 Interest of corporation controlled by you
Toyo International Investment Limited
Leung Hong Man
Leung Yiu Sing
Chu Shuet Fong
Lo Mei Sai
Time Lead Investments Limited

Dawnrays Pharmaceutical (Holdings) Headlines

No Headlines